A study by Le Heron et al. found that in bone cells from non-classic CF patients, loss of CFTR activity promotes inflammation-driven bone resorption via both reduced OPG production and increased prostaglandin E2 (PGE2) release. The gene discussed is CFTR; the disease is cystic fibrosis.